Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Olubunmi Afonja, Robert Kozak, Paul Petraro, Lisa A. Michaels, Prasad Mathew, Georg Lemm & Craig Kessler. (2016) Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Review of Hematology 9:12, pages 1151-1164.
Read now
Read now
Roberto Furlan, Sangeeta Krishnan & Jeffrey Vietri. (2015) Patient and parent preferences for characteristics of prophylactic treatment in hemophilia. Patient Preference and Adherence 9, pages 1687-1694.
Read now
Read now
Pier Mannuccio Mannucci & Massimo Franchini. (2014) Emerging drugs for hemophilia B. Expert Opinion on Emerging Drugs 19:3, pages 407-414.
Read now
Read now
Articles from other publishers (29)
Arjan van der Flier, Vu Hong, Zhan Liu, Peter Piepenhagen, Gregory Ulinski, Jennifer A. Dumont, Kelly D. Orcutt, Apollina Goel, Robert Peters & Joe Salas. (2023) Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice. Blood Coagulation & Fibrinolysis 34:6, pages 353-363.
Crossref
Crossref
Francesca Gorini, Michele Santoro, Anna Pierini, Lorena Mezzasalma, Silvia Baldacci, Elena Bargagli, Alessandra Boncristiano, Maurizia Rossana Brunetto, Paolo Cameli, Francesco Cappelli, Giancarlo Castaman, Barbara Coco, Maria Alice Donati, Renzo Guerrini, Silvia Linari, Vittoria Murro, Iacopo Olivotto, Paola Parronchi, Francesca Pochiero, Oliviero Rossi, Barbara Scappini, Andrea Sodi, Alessandro Maria Vannucchi & Alessio Coi. (2022) Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study. Frontiers in Pharmacology 13.
Crossref
Crossref
Beatrice Nolan, Anna KlukowskaAmy ShapiroAntoine Rauch, Michael Recht, Margaret RagniJulie CurtinSriya GunawardenaSutirtha MukhopadhyayDeepthi JayawardeneBent WindingKathelijn Fischer & Raina Liesner. (2021) Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances 5:13, pages 2732-2739.
Crossref
Crossref
Cedric Hermans, Maria Elisa Mancuso, Beatrice Nolan & K. John Pasi. (2021) Recombinant factor VIII Fc for the treatment of haemophilia A. European Journal of Haematology 106:6, pages 745-761.
Crossref
Crossref
A. Prieto Martín, J. Barbarroja Escudero, S. Haro Girón & A. Pérez Gómez. (2021) Avances y perspectivas actuales en recursos y estrategias terapéuticas: fármacos biológicos. Medicine - Programa de Formación Médica Continuada Acreditado 13:33, pages 1882-1892.
Crossref
Crossref
V. N. Konstantinova, T. A. Andreeva & A. V. Kim. (2021) Prospects for the use of prolonged concentrates of blood clotting factor IX in the treatment of hemophilia B. Russian Journal of Pediatric Hematology and Oncology 7:4, pages 56-61.
Crossref
Crossref
Tea Petrović, Gordan Lauc & Irena Trbojević-Akmačić. 2021. The Role of Glycosylation in Health and Disease. The Role of Glycosylation in Health and Disease
239
264
.
Anshu Shrestha, Jun Su, Nanxin Li, Christopher Barnowski, Nisha Jain, Katie Everson, Anupam Bapu Jena & Katharine Batt. (2021) Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors. Research and Practice in Thrombosis and Haemostasis 5:1, pages 94-103.
Crossref
Crossref
K. John Pasi, Kathelijn Fischer, Margaret Ragni, Roshni Kulkarni, Margareth C. Ozelo, Johnny Mahlangu, Amy Shapiro, Stephanie P’Ng, Hervé Chambost, Beatrice Nolan, Carolyn Bennett, Tadashi Matsushita, Bent Winding, Joachim Fruebis, Huixing Yuan, Dan Rudin & Johannes Oldenburg. (2020) Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study. Haemophilia 26:6.
Crossref
Crossref
Thomas Sinegre, Adeline Trayaud, Maryse Tardieu, Virginie Fourneyron, Laurie Talon, Marc G. Berger, Maxence Tillier, Stéphanie Senectaire, Piotr Gembara, Anne‐Lise Barbin, Aurélie Vaissade & Aurélien Lebreton. (2020) Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A single‐centre study. Haemophilia 26:3, pages 543-552.
Crossref
Crossref
Changhai Lei, Kewen Qian, Tian Li, Sheng Zhang, Wenyan Fu, Min Ding & Shi Hu. (2020) Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nature Communications 11:1.
Crossref
Crossref
Pan Liu, Jan Wysocki, Tomokazu Souma, Minghao Ye, Veronica Ramirez, Bisheng Zhou, Lisa D. Wilsbacher, Susan E. Quaggin, Daniel Batlle & Jing Jin. (2018) Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International 94:1, pages 114-125.
Crossref
Crossref
Carole Heath & Dean Pettit. 2018. Challenges in Protein Product Development. Challenges in Protein Product Development
545
558
.
Daniel Dixon, Serguei Tchessalov & Bakul Bhatnagar. 2018. Challenges in Protein Product Development. Challenges in Protein Product Development
407
439
.
S. von Mackensen, W. Kalnins, J. Krucker, J. Weiss, W. Miesbach, M. Albisetti, I. Pabinger & J. Oldenburg. (2017) Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia 23:4, pages 566-574.
Crossref
Crossref
Kim Schafer, James Munn, Kate Khair, Neelam Thukral, Angela Tom & Sally McAlister. (2017) Pharmacokinetics, Safety, and Efficacy of Recombinant Factor VIII Fc Fusion Protein. Journal of Infusion Nursing 40:1, pages 65-75.
Crossref
Crossref
A.H. Miners, S. Krishnan & K.J. Pasi. (2016) Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. Journal of Thrombosis and Haemostasis 14:11, pages 2141-2147.
Crossref
Crossref
G. Young & J. N. Mahlangu. (2016) Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia 22, pages 25-30.
Crossref
Crossref
Rodney M. Camire. (2016) Bioengineering factor Xa to treat bleeding. Thrombosis Research 141, pages S31-S33.
Crossref
Crossref
S. Kitchen, J. Blakemore, K.D. Friedman, D.P. Hart, R.H. Ko, D. Perry, S. Platton, D. Tan‐Castillo, G. Young & R.J. Luddington. (2016) A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assays. Journal of Thrombosis and Haemostasis 14:4, pages 757-764.
Crossref
Crossref
Rajiv K. Pruthi. (2016) Laboratory monitoring of new hemostatic agents for hemophilia. Seminars in Hematology 53:1, pages 28-34.
Crossref
Crossref
R.L. Lundblad. 2016. Encyclopedia of Cell Biology. Encyclopedia of Cell Biology
135
140
.
M. H. Sørensen, S. Andersen & M. Ezban. (2015) Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays. Haemophilia 21:6, pages 832-836.
Crossref
Crossref
J.-F. Schved. (2015) Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?. Transfusion Clinique et Biologique 22:3, pages 85-89.
Crossref
Crossref
Jennifer A. Dumont, Kenneth S. Loveday, David R. Light, Glenn F. Pierce & Haiyan Jiang. (2015) Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals. Thrombosis Research 136:2, pages 371-378.
Crossref
Crossref
Michelle P. Zeller, Khalid S. Al-Habsi, Mia Golder, Geraldine M. Walsh & William P. Sheffield. (2015) Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium. Transfusion Medicine Reviews 29:3, pages 181-194.
Crossref
Crossref
Midori SHIMA, Katsuyuki FUKUTAKE, Hideji HANABUSA, Tadashi MATSUSHITA, Masashi TAKI, Michio SAKAI, Toshiyuki HIRAKATAYingwen DONG, Shuanglian LI, Lynda M. CRISTIANO, Glenn F. PIERCE & Baisong MEI. (2015) Japanese subject subpopulation analysis of B-LONG: a Phase 3 study of long-acting recombinant factor IX Fc fusion protein. Japanese Journal of Thrombosis and Hemostasis 26:4, pages 420-429.
Crossref
Crossref
S. Krishnan, J. Vietri, R. Furlan & N. Duncan. (2015) Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia 21:1, pages 64-70.
Crossref
Crossref
John E. Schiel, Anthony Mire-Sluis & Darryl Davis. 2014. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space
1
34
.